Update to Reporting of COVID-19 Minor Deviations for NRG Oncology Studies (6/30/2022)
General Information on Potential Drug Interactions of Concomitant CTEP IND Agents and the SARS-CoV-2 Antiviral Drug PAXLOVID (3/3/2022)
NRG Oncology COVID-19 Vaccine Statement (2/23/2021)
Updated Message from NRG Oncology Leadership (12/15/2020)
Guidance for Shipment of CTEP Oral IND Agents (4/30/2021)
Resumption of Biospecimen Submissions for Breast and CRC Studies Memo (8/17/2020)
NRG Oncology Pharmacy Subcommittee: COVID-19 Vaccination
COVID-19 Vaccine Recommendation:
NRG Oncology defers to local institutional guidelines. In the absence of institutional guidelines, NRG Oncology recommends following current clinical practice guidelines from ASCO, ACS or NCCN. There are not specific contraindications to receiving COVID-19 vaccine on current NRG Oncology studies.
We understand that as a patient or family member of a patient participating in – or considering participating in, a research study may have questions related to your care and/or ability to complete the requirements of the research study given the current pandemic. See also the information linked below for cancer patients from the National Cancer Institute.
Medical facilities are instituting changes in how they operate in response to local risk, local or state requirements, and types of essential activities carried out at that particular facility. You should always check in if you have questions or concerns, according to what your research physician or other representative of your medical facility has directed you to do.
Some potential changes that may occurfor clinical trial participants are highlighted below:
Also see guidance for Cancer Patients from the National Cancer Institute
NRG Oncology remains committed to supporting your research efforts, whatever that may look like at your institution today. While the pandemic is commanding time, energy, and resources across the country and the world right now, the conduct of clinical research is a long-term commitment. Together, we will weather this storm and do our best for patients, Member Sites, study teams, and staff - and get to those research outcomes as best we can.
Protocol-specific guidance will be provided through the CTSU as always, and disseminated through our weekly broadcast or more frequently as required. This webpage links to the current guidance we are following from the NCI and CIRB. Come back often real-time updates will be posted here.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.